Maastricht, Netherlands

New BONOLIVE® clinical results published in peer reviewed journal. BONOLIVE® increases bone formation biomarkers and improves serum lipid profiles in postmenopausal women with osteopenia

BONOLIVE® is a clinically proven bone health ingredient. The results of a recent 12 month clinical study in 64 postmenopausal women with osteopenia showed significant effects on bone formation biomarkers and maintenance of a balanced bone turnover process and bone mineral density. Furthermore blood lipid profiles significantly improved, as shown by reduced total and LDL cholesterol and triglyceride levels. The results have been published in the Journal of Nutrition, Health & Aging.

BONOLIVE® is a proprietary polyphenol extract from olive leave which supports healthy bones. A recently completed double-blind, placebo-controlled 12 month intervention study in a population of postmenopausal women (n=32 per group) with identified osteopenia has confirmed preclinical data on the protective and balancing effect of BONOLIVE® on the bone remodelling process. Daily intake of BONOLIVE® over 12 months resulted in a consistent and continuous increase in plasma levels of the established bone formation biomarker osteocalcin, as compared to the placebo. This coincided with the maintenance of both the bone balance ratio, a marker for healthy bone remodelling, and bone mineral density in the lumbar spine. In contrast, both parameters deteriorated in the placebo group. Simultaneously, a significant decrease in total and LDL cholesterol and triglyceride levels was noted upon BONOLIVE® intake, suggesting additional health benefits of this highly bioavailable olive polyphenol extract.

The results of this study have been published in the Journal of Nutrition, Health & Aging


The study was performed by a team of scientists and clinicians from INRA, France and the osteoporosis outpatient clinic of the University of Lublin, Poland. The study was co-funded by BIOACTOR and FERRER HEALTHTECH, which exclusively manufactures BONOLIVE® and co- markets the product together with BIOACTOR in the Americas.

Additional information on BONOLIVE® and the science behind this unique health ingredient can be found HERE.

BioActor, based in Maastricht, Netherlands, is a product development company that supplies proprietary Active Nutritional Ingredients to the nutrition & healthcare industry. The company focuses on the development and sale of innovative ANI’s that address the metabolic syndrome and ageing related chronic health conditions. The goal is to provide the nutrition & healthcare industry with science-based innovations that confer a real health benefit to the consumer.

Ferrer HealthTech, headquartered in Barcelona, Spain, is the ingredient division of Ferrer, a privately owned pharmaceutical group. Ferrer HealthTech targets health and taste modulation with specialty ingredients from citrus and olive. The objective is to confer scientifically proven health and taste benefits to consumers from recognisable origins like citrus fruits and olive.

For further information, please contact BioActor